Sign In

Login

Password

Forgot Password ? Sign Up

Alzheimer-Krankheit (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Alzheimer-Krankheit" in German language version.

refsWebsite
Global rank German rank
80nih.gov
4th place
7th place
62doi.org
2nd place
3rd place
8web.archive.org
1st place
1st place
6redirecter.toolforge.org
33rd place
2nd place
5zdb-katalog.de
123rd place
6th place
4welt.de
201st place
11th place
4bund.de
2,092nd place
164th place
3aerztezeitung.de
low place
711th place
2deutsche-alzheimer.de
low place
5,856th place
2alzforum.org
low place
low place
2bbc.co.uk
8th place
37th place
2alz.org
low place
low place
2igel-monitor.de
low place
3,916th place
2schlosstheater-moers.de
low place
low place
1smh.com.au
132nd place
414th place
1alz.co.uk
low place
low place
1bcbs.com
low place
low place
1my-cme.de
low place
low place
1nytimes.com
7th place
19th place
1siemens.com
4,145th place
808th place
1clinicaltrials.gov
5,225th place
2,461st place
1tagesanzeiger.ch
2,194th place
170th place
1wiley.com
222nd place
272nd place
1iriss.org.uk
low place
low place
1ardalpha.de
low place
7,921st place
1awmf.org
5,401st place
312th place
1nice.org.uk
3,258th place
low place
1tagesspiegel.de
458th place
30th place
1g-ba.de
low place
1,618th place
1rochester.edu
2,691st place
3,014th place
1aerzteblatt.de
3,043rd place
200th place
1idw-online.de
5,704th place
362nd place
1bmjjournals.com
low place
low place
1eurekalert.org
3,538th place
1,951st place
1neurosciencenews.com
low place
low place
1g-o.de
low place
7,017th place
1bmj.com
1,226th place
1,116th place
1tu-darmstadt.de
low place
1,164th place
1sciencedaily.com
993rd place
1,265th place
1iqwig.de
low place
3,381st place
1webmedcentral.com
low place
low place
1thelancet.com
2,393rd place
2,660th place
1alzheimer-forschung.de
low place
low place
1dgkn.de
low place
low place
1medical-tribune.de
low place
4,040th place
1deadurl.invalid
low place
low place
1apa.at
low place
3,349th place
1mementoweb.org
317th place
14th place
1alzheimer-schweiz.ch
low place
low place
1derstandard.at
743rd place
45th place
1faz.net
240th place
13th place
1dhpv.de
low place
low place
1demenz-support.de
low place
low place
1taz.de
753rd place
43rd place
1lvr.de
low place
881st place
1spiegel.de
66th place
4th place
1youtube.com
9th place
9th place
1score11.de
low place
low place
1filmdienst.de
341st place
16th place
1daserste.de
1,904th place
123rd place
1rbb-online.de
5,150th place
335th place
1vfa.de
low place
low place

aerzteblatt.de

aerztezeitung.de

alz.co.uk

alz.org

alzforum.org

alzheimer-forschung.de

alzheimer-schweiz.ch

apa.at

science.apa.at

ardalpha.de

awmf.org

bbc.co.uk

news.bbc.co.uk

bcbs.com

bmj.com

jnnp.bmj.com

  • Weblink für Paper Paul T. Francis, Gordon K. Wilcock et al.: The cholinergic hypothesis of Alzheimer’s disease: a review of progress In: J Neurol Neurosurg Psychiatry (1999)

bmjjournals.com

bmj.bmjjournals.com

bund.de

bfr.bund.de

mobil.bfr.bund.de

clinicaltrials.gov

daserste.de

deadurl.invalid

demenz-support.de

derstandard.at

deutsche-alzheimer.de

dgkn.de

dhpv.de

doi.org

  • C. P. Ferri et al.: Global prevalence of dementia: a Delphi consensus study. In: Lancet. Band 366, Nr. 9503, Dezember 2005, S. 2112–2117, doi:10.1016/S0140-6736(05)67889-0. PMID 16360788. PMC 2850264 (freier Volltext).
  • A. Gołaszewska, W. Bik, T. Motyl, A. Orzechowski: Bridging the Gap between Alzheimer's Disease and Alzheimer's-like Diseases in Animals. In: International Journal of Molecular Sciences. Band 20, Nummer 7, April 2019, S. , doi:10.3390/ijms20071664, PMID 30987146, PMC 6479525 (freier Volltext) (Review).
  • J. J. Iliff et al.: Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. In: The Journal of neuroscience: the official journal of the Society for Neuroscience. Band 34, Nr. 49, Dezember 2014, S. 16180–16193, doi:10.1523/JNEUROSCI.3020-14.2014, PMID 25471560, PMC 4252540 (freier Volltext).
  • T. Jonsson et al.: A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. In: Nature. Band 488, Nr. 7409, August 2012, S. 96–99, doi:10.1038/nature11283. PMID 22801501.
  • E. Rogaeva et al.: The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. In: Nature genetics. Band 39, Nr. 2, Februar 2007, S. 168–177, doi:10.1038/ng1943. PMID 17220890. PMC 2657343 (freier Volltext).
  • F. Panza et al.: Amyloid-based immunotherapy for Alzheimer’s disease in the time of prevention trials: the way forward. In: Expert review of clinical immunology. Band 10, Nr. 3, März 2014, S. 405–419, doi:10.1586/1744666X.2014.883921, PMID 24490853 (Review).
  • F. Panza et al.: Is there still any hope for amyloid-based immunotherapy for Alzheimer’s disease? In: Current opinion in psychiatry. Band 27, Nr. 2, März 2014, S. 128–137, doi:10.1097/YCO.0000000000000041, PMID 24445401 (Review).
  • J. M. Tarasoff-Conway et al.: Clearance systems in the brain-implications for Alzheimer disease. In: Nature reviews. Neurology. Band 11, Nr. 8, August 2015, S. 457–470, doi:10.1038/nrneurol.2015.119, PMID 26195256, PMC 4694579 (freier Volltext) (Review).
  • S. J. Soscia et al.: The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. In: PloS one. Band 5, Nr. 3, 2010, S. e9505, doi:10.1371/journal.pone.0009505. PMID 20209079. PMC 2831066 (freier Volltext).
  • Antonios Douros, Zharmaine Ante, Carlo A. Fallone, Laurent Azoulay, Christel Renoux, Samy Suissa, Paul Brassard: Clinically apparent Helicobacter pylori infection and the risk of incident Alzheimer's disease: A population‐based nested case‐control study. In: Alzheimer's & Dementia. 13. Dezember 2023, ISSN 1552-5260, doi:10.1002/alz.13561 (wiley.com [abgerufen am 2. Januar 2024]).
  • Theodore I. Lidsky: Is the Aluminum Hypothesis dead? In: Journal of Occupational and Environmental Medicine. Band 56, 5 Suppl, Mai 2014, S. S73–79, doi:10.1097/JOM.0000000000000063, PMID 24806729, PMC 4131942 (freier Volltext) – (englisch).
  • Lilian Calderón-Garcidueñas et al.: Hallmarks of Alzheimer disease are evolving relentlessly in Metropolitan Mexico City infants, children and young adults. APOE4 carriers have higher suicide risk and higher odds of reaching NFT stage V at ≤ 40 years of age. In: Environmental Research. Band 164, 2018, S. 475, doi:10.1016/j.envres.2018.03.023.
  • E. W. Twamley, S. A. Ropacki, M. W. Bondi: Neuropsychological and neuroimaging changes in preclinical Alzheimer’s disease. In: J Int Neuropsychol Soc. Band 12, Nr. 5, 2006, S. 707–735, doi:10.1017/S1355617706060863, PMID 16961952.
  • C. R. Jack et al.: Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. In: Alzheimer’s & dementia: the journal of the Alzheimer’s Association. Band 7, Nr. 3, Mai 2011, S. 257–262, doi:10.1016/j.jalz.2011.03.004. PMID 21514247. PMC 3096735 (freier Volltext).
  • G. B. Frisoni et al.: Revised criteria for Alzheimer’s disease: what are the lessons for clinicians? In: The Lancet. Neurology. Band 10, Nr. 7, Juli 2011, S. 598–601, doi:10.1016/S1474-4422(11)70126-0. PMID 21683925.
  • R. A. Sperling et al.: Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. In: Alzheimer’s & dementia. Band 7, Nr. 3, Mai 2011, S. 280–292, doi:10.1016/j.jalz.2011.03.003. PMID 21514248. PMC 3220946 (freier Volltext).
  • M. S. Albert et al.: The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. In: Alzheimer’s & dementia: the journal of the Alzheimer’s Association. Band 7, Nr. 3, Mai 2011, S. 270–279, doi:10.1016/j.jalz.2011.03.008. PMID 21514249. PMC 3312027 (freier Volltext).
  • G. M. McKhann et al.: The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. In: Alzheimer’s & dementia: the journal of the Alzheimer’s Association. Band 7, Nr. 3, Mai 2011, S. 263–269, doi:10.1016/j.jalz.2011.03.005. PMID 21514250. PMC 3312024 (freier Volltext).
  • H.-J. Gertz, A. Kurz: Diagnose ohne Therapie. Frühdiagnostik der Alzheimer-Krankheit im Stadium der leichten kognitiven Beeinträchtigung. In: Der Nervenarzt. Band 82, Nr. 9, 2011, doi:10.1007/s00115-010-3213-3
  • H. Barthel et al.: Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. In: The Lancet. Neurology. Band 10, Nr. 5, Mai 2011, S. 424–435, doi:10.1016/S1474-4422(11)70077-1. PMID 21481640.
  • Thomas Hauser et al..: Mild cognitive impairment. Diagnostische Wertigkeit verschiedener MRT-Techniken. In: Der Radiologe. 2011; 51: S. 285–292 doi:10.1007/s00117-010-2094-6
  • Marcus Bauser, Lutz Lehmann: Positronen-Emissions-Tomographie. In: Chemie in unserer Zeit. Band 46, Nr. 2, 2012, S. 94, doi:10.1002/ciuz.201200564.
  • Oliver Wirths et al.: Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. In: The Journal of Biological Chemistry. Band 285, Nr. 53, 2010, S. 41517–41524, doi:10.1074/jbc.M110.178707, PMID 20971852, PMC 3009878 (freier Volltext).
  • S. López-Ortiz, S. Lista, P. L. Valenzuela, J. Pinto-Fraga, R. Carmona, F. Caraci, G. Caruso, N. Toschi, E. Emanuele, A. Gabelle, R. Nisticò, F. Garaci, A. Lucia, A. Santos-Lozano: Effects of physical activity and exercise interventions on Alzheimer's disease: an umbrella review of existing meta-analyses. In: Journal of neurology. Band 270, Nr. 2, Februar 2023, S. 711–725, doi:10.1007/s00415-022-11454-8, PMID 36342524 (Review).
  • P. Iso-Markku, U. M. Kujala, K. Knittle, J. Polet, E. Vuoksimaa, K. Waller: Physical activity as a protective factor for dementia and Alzheimer's disease: systematic review, meta-analysis and quality assessment of cohort and case-control studies. In: British journal of sports medicine. Band 56, Nr. 12, Juni 2022, S. 701–709, doi:10.1136/bjsports-2021-104981, PMID 35301183, PMC 9163715 (freier Volltext) (Review).
  • K. I. Erickson, A. M. Weinstein, O. L. Lopez: Physical activity, brain plasticity, and Alzheimer's disease. In: Archives of medical research. Band 43, Nr. 8, November 2012, S. 615–621, doi:10.1016/j.arcmed.2012.09.008, PMID 23085449, PMC 3567914 (freier Volltext) (Review).
  • K. A. Intlekofer, C. W. Cotman: Exercise counteracts declining hippocampal function in aging and Alzheimer's disease. In: Neurobiology of Disease. Band 57, September 2013, S. 47–55, doi:10.1016/j.nbd.2012.06.011, PMID 22750524 (Review).
  • B. M. Brown, J. J. Peiffer, R. N. Martins: Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease? In: Molecular Psychiatry. Band 18, Nummer 8, August 2013, S. 864–874, doi:10.1038/mp.2012.162, PMID 23164816 (Review).
  • Harsh Shah et al.: Revisiting the Role of Vitamins and Minerals in Alzheimer's Disease. In: Antioxidants (Basel, Switzerland). Band 12, Nr. 2, 8. Februar 2023, S. 415, doi:10.3390/antiox12020415, PMID 36829974, PMC 9952129 (freier Volltext) – (englisch).
  • P. E. Cramer et al.: ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. In: Science. Band 335, Nr. 6075, März 2012, S. 1503–1506, doi:10.1126/science.1217697. PMID 22323736. PMC 3651582 (freier Volltext).
  • E. O’Hare et al.: Lack of support for bexarotene as a treatment for Alzheimer’s disease. In: Neuropharmacology. [elektronische Veröffentlichung vor dem Druck] Mai 2015, doi:10.1016/j.neuropharm.2015.04.020, PMID 26025659.
  • C. Balducci et al.: The Continuing Failure of Bexarotene in Alzheimer’s Disease Mice. In: Journal of Alzheimer’s disease: JAD. [elektronische Veröffentlichung vor dem Druck] März 2015, doi:10.3233/JAD-150029, PMID 25777514.
  • B. Tousi: The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence. In: Neuropsychiatric disease and treatment. Band 11, 2015, S. 311–315, doi:10.2147/NDT.S61309, PMID 25709453, PMC 4327563 (freier Volltext) (Review).
  • B. S. Wang, H. Wang, Z. H. Wei, Y. Y. Song, L. Zhang, H. Z. Chen: Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis. In: Journal of Neural Transmission. Band 116, Nr. 4, 2009, S. 457–465, doi:10.1007/s00702-009-0189-x, PMID 19221692.
  • B. Winblad, J. Cummings, N. Andreasen et al.: A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. In: International Journal of Geriatric Psychiatry, Band 22, Nr. 5, S. 456–467, May 2007 doi:10.1002/gps.1788 PMID 17380489
  • T. Lempert, T. Bschor: [Treatment of Alzheimer’s disease according to the S3 guidelines on dementia. Choline esterase inhibitors for all and for ever?]. In: Der Nervenarzt. Band 82, Nr. 1, Januar 2011, S. 90–91, doi:10.1007/s00115-010-3233-z. PMID 21274696.
  • T. Wyss-Coray, L. Mucke: Ibuprofen, inflammation and Alzheimer disease. In: Nature medicine. Band 6, Nr. 9, September 2000, S. 973–974, doi:10.1038/79661. PMID 10973311.
  • T. Morihara et al.: Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer’s models. In: Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. Band 30, Nr. 6, Juni 2005, S. 1111–1120, doi:10.1038/sj.npp.1300668. PMID 15688088.
  • A. C. McKee et al.: Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. In: Brain research. Band 1207, Mai 2008, S. 225–236, doi:10.1016/j.brainres.2008.01.095. PMID 18374906. PMC 2587244 (freier Volltext).
  • M. Sastre et al.: Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. In: Proceedings of the National Academy of Sciences. Band 103, Nr. 2, Januar 2006, S. 443–448, doi:10.1073/pnas.0503839103. PMID 16407166. PMC 1326151 (freier Volltext).
  • N. Tabet, H. Feldmand: Ibuprofen for Alzheimer’s disease. In: The Cochrane database of systematic reviews. Nr. 2, 2003, S. CD004031, doi:10.1002/14651858.CD004031. PMID 12804498. (Review).
  • B. De Strooper, G. König: An inflammatory drug prospect. In: Nature. Band 414, Nr. 6860, November 2001, S. 159–160, doi:10.1038/35102656. PMID 11700538.
  • M. Krohn et al.: Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice. In: The Journal of clinical investigation. Band 121, Nr. 10, Oktober 2011, S. 3924–3931, doi:10.1172/JCI57867. PMID 21881209. PMC 3195473 (freier Volltext).
  • R. McShane, A. Areosa Sastre, N. Minakaran: Memantine for dementia. In: The Cochrane database of systematic reviews. Nr. 2, 2006, S. CD003154, doi:10.1002/14651858.CD003154.pub5. PMID 16625572. (Review).
  • J. Birks, Evans J. Grimley: Ginkgo biloba for cognitive impairment and dementia. In: Cochrane Database Syst Rev. Nr. 2, 2007, S. CD003120, doi:10.1002/14651858.CD003120.pub2, PMID 17443523.
  • S. T. DeKosky, A. Fitzpatrick, D. G. Ives, J. Saxton, J. Williamson, O. L. Lopez, G. Burke, L. Fried, L. H. Kuller, J. Robbins, R. Tracy, N. Woolard, L. Dunn, R. Kronmal, R. Nahin, C. Furberg: The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. In: Contemp Clin Trials. Band 27, Nr. 3, 2006, S. 238–253, doi:10.1016/j.cct.2006.02.007, PMID 16627007.
  • B. E. Snitz et al.: Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. In: JAMA. Band 302, Nr. 24, Dezember 2009, S. 2663–2670, doi:10.1001/jama.2009.1913. PMID 20040554. PMC 2832285 (freier Volltext).
  • Stefan Weinmann et al.: Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. In: BMC Geriatrics 2010, 10:14 doi:10.1186/1471-2318-10-14
  • David Sanchez-Rodriguez et al.: Chaperone activity and protective effect against Aβ-induced cytotoxicity of Artocarpus camansi Blanco and Amaranthus dubius Mart. ex Thell seed protein extracts. In: Pharmaceuticals 2023, 16:6 doi:10.3390/ph16060820
  • S. Krishnan, R. Cairns, R. Howard: Cannabinoids for the treatment of dementia. In: The Cochrane database of systematic reviews. Nr. 2, 2009, S. CD007204, doi:10.1002/14651858.CD007204.pub2, PMID 19370677 (Review).
  • S. Craft et al.: Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. In: Archives of neurology. Band 69, Nr. 1, Januar 2012, S. 29–38, doi:10.1001/archneurol.2011.233. PMID 21911655. PMC 3260944 (freier Volltext).
  • Jacobo Mintzer, Krista L. Lanctôt, Roberta W. Scherer, Paul B. Rosenberg, Nathan Herrmann: Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. In: JAMA neurology. Band 78, Nr. 11, 1. November 2021, ISSN 2168-6157, S. 1324–1332, doi:10.1001/jamaneurol.2021.3356, PMID 34570180, PMC 8477302 (freier Volltext).
  • Carolyn Fredericks: Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care? In: JAMA Neurology. Band 78, Nr. 11, 1. November 2021, ISSN 2168-6149, S. 1311, doi:10.1001/jamaneurol.2021.2942.
  • M. W. Dysken et al.: Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. In: JAMA. Band 311, Nr. 1, Januar 2014, S. 33–44, doi:10.1001/jama.2013.282834. PMID 24381967. PMC 4109898 (freier Volltext).
  • M. Sano et al.: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. In: The New England Journal of Medicine. Band 336, Nr. 17, April 1997, S. 1216–1222, doi:10.1056/NEJM199704243361704. PMID 9110909.
  • R. C. Petersen et al.: Vitamin E and donepezil for the treatment of mild cognitive impairment. In: The New England Journal of Medicine. Band 352, Nr. 23, Juni 2005, S. 2379–2388, doi:10.1056/NEJMoa050151. PMID 15829527.
  • J. H. Kang et al.: A randomized trial of vitamin E supplementation and cognitive function in women. In: Archives of internal medicine. Band 166, Nr. 22, 2006 Dec 11-25, S. 2462–2468, doi:10.1001/archinte.166.22.2462. PMID 17159011.
  • J. H. Kang et al.: Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women’s Antioxidant and Cardiovascular Study. In: Circulation. Band 119, Nr. 21, Juni 2009, S. 2772–2780, doi:10.1161/CIRCULATIONAHA.108.816900. PMID 19451353. PMC 2752297 (freier Volltext).
  • Hilkka Soininen et al.: 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. In: The Lancet Neurology. Band 0, Nr. 0, ISSN 1474-4422, doi:10.1016/S1474-4422(17)30332-0 (Online [abgerufen am 11. November 2017]).
  • S3-Leitlinie Demenzen. 2017, doi:10.1007/978-3-662-53875-3.
  • F. G. Boess, M. Lieb, E. Schneider, T. M. Zimmermann, R. Dodel: Kosten der Alzheimer-Erkrankung in Deutschland – aktuelle Ergebnisse der GERAS-Beobachtungsstudie. In: Gesundheitsökonomie & Qualitätsmanagement. Band 21, Nr. 5. Thieme, Oktober 2016, ISSN 1432-2625, S. 232–241, doi:10.1055/s-0042-100956.
  • U. Müller, P. Winter, M. B. Graeber: A presenilin 1 mutation in the first case of Alzheimer’s disease. In: The Lancet. Neurology. Band 12, Nr. 2, Februar 2013, S. 129–130, doi:10.1016/S1474-4422(12)70307-1. PMID 23246540.

eurekalert.org

faz.net

filmdienst.de

g-ba.de

g-o.de

idw-online.de

igel-monitor.de

  • Hirnleistungs-Check zur Früherkennung einer Demenz. IGeL-Monitor; abgerufen am 15. Januar 2019. Wichtigste Quellen darin: Meta-Analyse Tsoi 2016. – KK Tsoi, HW Hirai, JY Chan, TC. Kwok: Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials. In: Journal of the American Medical Directors Association, 2016, 17, S. 24–30, PMID 26392193; sowie Systematisches Review Lin et al. 2013 – J. S. Lin, E. O’Connor, R. C. Rossom, L. A. Perdue, E. Eckstrom: Screening for cognitive impairment in older adults: A systematic review for the U.S. Preventive Services Task Force. In: Annals of internal medicine, 2013, 159, S. 601–612, PMID 24354019. Mehr zur Begründung der Bewertung in Evidenz kompakt. (PDF; 297 kB) abgerufen am 15. Januar 2019.
  • MRT zur Früherkennung einer Alzheimer-Demenz. IGeL-Monitor; abgerufen am 15. Januar 2019. Wichtigste Quellen darin: NICE-Leitlinie von 2011. (National Institute for Health and Clinical Excellence der britischen Gesundheitsbehörde NHS) sowie Meta-Analyse Schmand et al. 2010. – B. Schmand, H. M. Huizenga, W. A. van Gool: Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer’s disease. In: Psychological Medicine, Januar 2010, 40 (1): S. 135–145, PMID 19863841. Mehr zur Begründung der Bewertung in der Evidenzsynthese. (PDF; 104 kB) abgerufen am 15. Januar 2019.

iqwig.de

iriss.org.uk

lx.iriss.org.uk

lvr.de

einestages.lvr.de

medical-tribune.de

mementoweb.org

timetravel.mementoweb.org

my-cme.de

neurosciencenews.com

nice.org.uk

  • MRT zur Früherkennung einer Alzheimer-Demenz. IGeL-Monitor; abgerufen am 15. Januar 2019. Wichtigste Quellen darin: NICE-Leitlinie von 2011. (National Institute for Health and Clinical Excellence der britischen Gesundheitsbehörde NHS) sowie Meta-Analyse Schmand et al. 2010. – B. Schmand, H. M. Huizenga, W. A. van Gool: Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer’s disease. In: Psychological Medicine, Januar 2010, 40 (1): S. 135–145, PMID 19863841. Mehr zur Begründung der Bewertung in der Evidenzsynthese. (PDF; 104 kB) abgerufen am 15. Januar 2019.

nih.gov

ncbi.nlm.nih.gov

  • C. P. Ferri et al.: Global prevalence of dementia: a Delphi consensus study. In: Lancet. Band 366, Nr. 9503, Dezember 2005, S. 2112–2117, doi:10.1016/S0140-6736(05)67889-0. PMID 16360788. PMC 2850264 (freier Volltext).
  • A. Gołaszewska, W. Bik, T. Motyl, A. Orzechowski: Bridging the Gap between Alzheimer's Disease and Alzheimer's-like Diseases in Animals. In: International Journal of Molecular Sciences. Band 20, Nummer 7, April 2019, S. , doi:10.3390/ijms20071664, PMID 30987146, PMC 6479525 (freier Volltext) (Review).
  • J. J. Iliff et al.: Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. In: The Journal of neuroscience: the official journal of the Society for Neuroscience. Band 34, Nr. 49, Dezember 2014, S. 16180–16193, doi:10.1523/JNEUROSCI.3020-14.2014, PMID 25471560, PMC 4252540 (freier Volltext).
  • T. Jonsson et al.: A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. In: Nature. Band 488, Nr. 7409, August 2012, S. 96–99, doi:10.1038/nature11283. PMID 22801501.
  • E. Rogaeva et al.: The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. In: Nature genetics. Band 39, Nr. 2, Februar 2007, S. 168–177, doi:10.1038/ng1943. PMID 17220890. PMC 2657343 (freier Volltext).
  • F. Lopera et al.: Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. In: JAMA. Band 277, Nr. 10, März 1997, S. 793–799, PMID 9052708.
  • F. Panza et al.: Amyloid-based immunotherapy for Alzheimer’s disease in the time of prevention trials: the way forward. In: Expert review of clinical immunology. Band 10, Nr. 3, März 2014, S. 405–419, doi:10.1586/1744666X.2014.883921, PMID 24490853 (Review).
  • F. Panza et al.: Is there still any hope for amyloid-based immunotherapy for Alzheimer’s disease? In: Current opinion in psychiatry. Band 27, Nr. 2, März 2014, S. 128–137, doi:10.1097/YCO.0000000000000041, PMID 24445401 (Review).
  • J. M. Tarasoff-Conway et al.: Clearance systems in the brain-implications for Alzheimer disease. In: Nature reviews. Neurology. Band 11, Nr. 8, August 2015, S. 457–470, doi:10.1038/nrneurol.2015.119, PMID 26195256, PMC 4694579 (freier Volltext) (Review).
  • S. J. Soscia et al.: The Alzheimer’s disease-associated amyloid beta-protein is an antimicrobial peptide. In: PloS one. Band 5, Nr. 3, 2010, S. e9505, doi:10.1371/journal.pone.0009505. PMID 20209079. PMC 2831066 (freier Volltext).
  • R. Mayeux, R. Ottman, M. Tang, L. Noboa-Bauza, K. Marder, B. Gurland, Y. Stern: Genetic susceptibility and head injury as risk factors for Alzheimer’s disease among community-dwelling elderly persons and their first-degree relatives. In: Ann Neurol. Band 33, Nr. 5, 1993, S. 494–501, PMID 8498827.
  • K. F. Neumann, L. Rojo, L. P. Navarrete, G. Farías, P. Reyes, R. B. Maccioni: Insulin resistance and Alzheimer’s disease: molecular links & clinical implications. In: Curr Alzheimer Res.:. Nr. 5 (5), Oktober 2008, S. 438–447, PMID 18855585.
  • J. S. Roriz-Filho, T. M. Sá-Roriz, I. Rosset, A. L. Camozzato, A. C. Santos, M. L. Chaves, J. C. Moriguti, M. Roriz-Cruz: (Pre)diabetes, brain aging, and cognition. In: Biochim Biophys Acta. 2009, S. 432–443, PMID 19135149.
  • W. Q. Qiu, M. F. Folstein: Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer’s disease: review and hypothesis. In: Neurobiol Aging. Feb; 27 (2), 2006, S. 190–198, PMID 19135149.
  • O. S. Kofman, V. H. Macmillan: Diffuse cerebral atrophy. In: Applied therapeutics. Band 12, Nr. 4, April 1970, S. 24–26, PMID 5446326.
  • M. Crisby, L. Carlson, B. Winblad: Statins in the prevention and treatment of Alzheimer disease. In: Alzheimer Disease & Associated Disorders. Band 16, Nr. 3, 2002, S. 131–136, PMID 12218642.
  • P. Kehoe, G. Wilcock: Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer’s disease? In: Lancet neurology. Band 6, Nr. 4, 2007, S. 373–378, PMID 17362841.
  • Theodore I. Lidsky: Is the Aluminum Hypothesis dead? In: Journal of Occupational and Environmental Medicine. Band 56, 5 Suppl, Mai 2014, S. S73–79, doi:10.1097/JOM.0000000000000063, PMID 24806729, PMC 4131942 (freier Volltext) – (englisch).
  • Hirnleistungs-Check zur Früherkennung einer Demenz. IGeL-Monitor; abgerufen am 15. Januar 2019. Wichtigste Quellen darin: Meta-Analyse Tsoi 2016. – KK Tsoi, HW Hirai, JY Chan, TC. Kwok: Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials. In: Journal of the American Medical Directors Association, 2016, 17, S. 24–30, PMID 26392193; sowie Systematisches Review Lin et al. 2013 – J. S. Lin, E. O’Connor, R. C. Rossom, L. A. Perdue, E. Eckstrom: Screening for cognitive impairment in older adults: A systematic review for the U.S. Preventive Services Task Force. In: Annals of internal medicine, 2013, 159, S. 601–612, PMID 24354019. Mehr zur Begründung der Bewertung in Evidenz kompakt. (PDF; 297 kB) abgerufen am 15. Januar 2019.
  • MRT zur Früherkennung einer Alzheimer-Demenz. IGeL-Monitor; abgerufen am 15. Januar 2019. Wichtigste Quellen darin: NICE-Leitlinie von 2011. (National Institute for Health and Clinical Excellence der britischen Gesundheitsbehörde NHS) sowie Meta-Analyse Schmand et al. 2010. – B. Schmand, H. M. Huizenga, W. A. van Gool: Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer’s disease. In: Psychological Medicine, Januar 2010, 40 (1): S. 135–145, PMID 19863841. Mehr zur Begründung der Bewertung in der Evidenzsynthese. (PDF; 104 kB) abgerufen am 15. Januar 2019.
  • R. T. Linn et al.: The 'preclinical phase' of probable Alzheimer’s disease. A 13-year prospective study of the Framingham cohort. In: Arch Neurol. Band 52, Nr. 5, 1995, S. 485–490, PMID 7733843.
  • J. Saxton et al.: Preclinical Alzheimer disease: neuropsychological test performance 1.5 to 8 years prior to onset. In: Neurology. Band 63, Nr. 12, 2004, S. 2341–2347, PMID 15623697.
  • E. W. Twamley, S. A. Ropacki, M. W. Bondi: Neuropsychological and neuroimaging changes in preclinical Alzheimer’s disease. In: J Int Neuropsychol Soc. Band 12, Nr. 5, 2006, S. 707–735, doi:10.1017/S1355617706060863, PMID 16961952.
  • C. R. Jack et al.: Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. In: Alzheimer’s & dementia: the journal of the Alzheimer’s Association. Band 7, Nr. 3, Mai 2011, S. 257–262, doi:10.1016/j.jalz.2011.03.004. PMID 21514247. PMC 3096735 (freier Volltext).
  • G. B. Frisoni et al.: Revised criteria for Alzheimer’s disease: what are the lessons for clinicians? In: The Lancet. Neurology. Band 10, Nr. 7, Juli 2011, S. 598–601, doi:10.1016/S1474-4422(11)70126-0. PMID 21683925.
  • R. A. Sperling et al.: Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. In: Alzheimer’s & dementia. Band 7, Nr. 3, Mai 2011, S. 280–292, doi:10.1016/j.jalz.2011.03.003. PMID 21514248. PMC 3220946 (freier Volltext).
  • M. S. Albert et al.: The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. In: Alzheimer’s & dementia: the journal of the Alzheimer’s Association. Band 7, Nr. 3, Mai 2011, S. 270–279, doi:10.1016/j.jalz.2011.03.008. PMID 21514249. PMC 3312027 (freier Volltext).
  • G. M. McKhann et al.: The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. In: Alzheimer’s & dementia: the journal of the Alzheimer’s Association. Band 7, Nr. 3, Mai 2011, S. 263–269, doi:10.1016/j.jalz.2011.03.005. PMID 21514250. PMC 3312024 (freier Volltext).
  • H. Barthel et al.: Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. In: The Lancet. Neurology. Band 10, Nr. 5, Mai 2011, S. 424–435, doi:10.1016/S1474-4422(11)70077-1. PMID 21481640.
  • L. Mucke: Neuroscience: Alzheimer’s disease. In: Nature. Band 461, 2009, S. 895–897, PMID 19829367.
  • H. Förstl, A. Kurz: Clinical features of Alzheimer’s disease. In: European Archives of Psychiatry and Clinical Neuroscience. Band 249, Nr. 6, 1999, S. 288–290, PMID 10653284.
  • G. A. Carlesimo, M. Oscar-Berman: Memory deficits in Alzheimer’s patients: a comprehensive review. In: Neuropsychology Review. Band 3, Nr. 2, 1992, S. 119–169, PMID 1300219.
  • M. Jelicic, A. E. Bonebakker, B. Bonke: Implicit memory performance of patients with Alzheimer’s disease: a brief review. In: International psychogeriatrics / IPA. Band 7, Nr. 3, 1995, S. 385–392, PMID 8821346.
  • E. M. Frank: Effect of Alzheimer’s disease on communication function. In: Journal of the South Carolina Medical Association (1975). Band 90, Nr. 9, 1994, S. 417–423, PMID 7967534.
  • J. T. Becker, A. A. Overman: [The semantic memory deficit in Alzheimer’s disease]. In: Revista De Neurologia. Band 35, Nr. 8, 2002, S. 777–783, PMID 12402233.
  • J. R. Hodges, K. Patterson: Is semantic memory consistently impaired early in the course of Alzheimer’s disease? Neuroanatomical and diagnostic implications. In: Neuropsychologia. Band 33, Nr. 4, 1995, S. 441–459, PMID 7617154.
  • T. Benke: Two forms of apraxia in Alzheimer’s disease. In: Cortex; a Journal Devoted to the Study of the Nervous System and Behavior. Band 29, Nr. 4, 1993, S. 715–725, PMID 8124945.
  • Oliver Wirths et al.: Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. In: The Journal of Biological Chemistry. Band 285, Nr. 53, 2010, S. 41517–41524, doi:10.1074/jbc.M110.178707, PMID 20971852, PMC 3009878 (freier Volltext).
  • S. López-Ortiz, S. Lista, P. L. Valenzuela, J. Pinto-Fraga, R. Carmona, F. Caraci, G. Caruso, N. Toschi, E. Emanuele, A. Gabelle, R. Nisticò, F. Garaci, A. Lucia, A. Santos-Lozano: Effects of physical activity and exercise interventions on Alzheimer's disease: an umbrella review of existing meta-analyses. In: Journal of neurology. Band 270, Nr. 2, Februar 2023, S. 711–725, doi:10.1007/s00415-022-11454-8, PMID 36342524 (Review).
  • P. Iso-Markku, U. M. Kujala, K. Knittle, J. Polet, E. Vuoksimaa, K. Waller: Physical activity as a protective factor for dementia and Alzheimer's disease: systematic review, meta-analysis and quality assessment of cohort and case-control studies. In: British journal of sports medicine. Band 56, Nr. 12, Juni 2022, S. 701–709, doi:10.1136/bjsports-2021-104981, PMID 35301183, PMC 9163715 (freier Volltext) (Review).
  • K. I. Erickson, A. M. Weinstein, O. L. Lopez: Physical activity, brain plasticity, and Alzheimer's disease. In: Archives of medical research. Band 43, Nr. 8, November 2012, S. 615–621, doi:10.1016/j.arcmed.2012.09.008, PMID 23085449, PMC 3567914 (freier Volltext) (Review).
  • K. A. Intlekofer, C. W. Cotman: Exercise counteracts declining hippocampal function in aging and Alzheimer's disease. In: Neurobiology of Disease. Band 57, September 2013, S. 47–55, doi:10.1016/j.nbd.2012.06.011, PMID 22750524 (Review).
  • B. M. Brown, J. J. Peiffer, R. N. Martins: Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease? In: Molecular Psychiatry. Band 18, Nummer 8, August 2013, S. 864–874, doi:10.1038/mp.2012.162, PMID 23164816 (Review).
  • Harsh Shah et al.: Revisiting the Role of Vitamins and Minerals in Alzheimer's Disease. In: Antioxidants (Basel, Switzerland). Band 12, Nr. 2, 8. Februar 2023, S. 415, doi:10.3390/antiox12020415, PMID 36829974, PMC 9952129 (freier Volltext) – (englisch).
  • P. E. Cramer et al.: ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. In: Science. Band 335, Nr. 6075, März 2012, S. 1503–1506, doi:10.1126/science.1217697. PMID 22323736. PMC 3651582 (freier Volltext).
  • E. O’Hare et al.: Lack of support for bexarotene as a treatment for Alzheimer’s disease. In: Neuropharmacology. [elektronische Veröffentlichung vor dem Druck] Mai 2015, doi:10.1016/j.neuropharm.2015.04.020, PMID 26025659.
  • C. Balducci et al.: The Continuing Failure of Bexarotene in Alzheimer’s Disease Mice. In: Journal of Alzheimer’s disease: JAD. [elektronische Veröffentlichung vor dem Druck] März 2015, doi:10.3233/JAD-150029, PMID 25777514.
  • B. Tousi: The emerging role of bexarotene in the treatment of Alzheimer’s disease: current evidence. In: Neuropsychiatric disease and treatment. Band 11, 2015, S. 311–315, doi:10.2147/NDT.S61309, PMID 25709453, PMC 4327563 (freier Volltext) (Review).
  • B. S. Wang, H. Wang, Z. H. Wei, Y. Y. Song, L. Zhang, H. Z. Chen: Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer’s disease: an updated meta-analysis. In: Journal of Neural Transmission. Band 116, Nr. 4, 2009, S. 457–465, doi:10.1007/s00702-009-0189-x, PMID 19221692.
  • B. Winblad, J. Cummings, N. Andreasen et al.: A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. In: International Journal of Geriatric Psychiatry, Band 22, Nr. 5, S. 456–467, May 2007 doi:10.1002/gps.1788 PMID 17380489
  • H. Kaduszkiewicz, T. Zimmermann, H. P. Beck-Bornholdt, Hendrik van den Bussche: Cholinesterase inhibitors for patients with Alzheimer’s disease: systematic review of randomised clinical trials. In: BMJ (Clinical Research Ed.). Band 331, Nr. 7512, August 2005, S. 321–327, PMID 16081444, PMC 1183129 (freier Volltext).
  • T. Lempert, T. Bschor: [Treatment of Alzheimer’s disease according to the S3 guidelines on dementia. Choline esterase inhibitors for all and for ever?]. In: Der Nervenarzt. Band 82, Nr. 1, Januar 2011, S. 90–91, doi:10.1007/s00115-010-3233-z. PMID 21274696.
  • J. C. Breitner, K. A. Welsh et al.: Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. In: Neurobiology of Aging Volume 16, Issue 4, Pages 523-530, July 1995 PMID 8544901
  • T. Wyss-Coray, L. Mucke: Ibuprofen, inflammation and Alzheimer disease. In: Nature medicine. Band 6, Nr. 9, September 2000, S. 973–974, doi:10.1038/79661. PMID 10973311.
  • D. Dokmeci: Ibuprofen and Alzheimer’s disease. In: Folia medica. Band 46, Nr. 2, 2004, S. 5–10, PMID 15506544. (Review).
  • T. Morihara et al.: Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer’s models. In: Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. Band 30, Nr. 6, Juni 2005, S. 1111–1120, doi:10.1038/sj.npp.1300668. PMID 15688088.
  • A. C. McKee et al.: Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. In: Brain research. Band 1207, Mai 2008, S. 225–236, doi:10.1016/j.brainres.2008.01.095. PMID 18374906. PMC 2587244 (freier Volltext).
  • M. Sastre et al.: Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. In: Proceedings of the National Academy of Sciences. Band 103, Nr. 2, Januar 2006, S. 443–448, doi:10.1073/pnas.0503839103. PMID 16407166. PMC 1326151 (freier Volltext).
  • N. Tabet, H. Feldmand: Ibuprofen for Alzheimer’s disease. In: The Cochrane database of systematic reviews. Nr. 2, 2003, S. CD004031, doi:10.1002/14651858.CD004031. PMID 12804498. (Review).
  • B. De Strooper, G. König: An inflammatory drug prospect. In: Nature. Band 414, Nr. 6860, November 2001, S. 159–160, doi:10.1038/35102656. PMID 11700538.
  • M. Krohn et al.: Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice. In: The Journal of clinical investigation. Band 121, Nr. 10, Oktober 2011, S. 3924–3931, doi:10.1172/JCI57867. PMID 21881209. PMC 3195473 (freier Volltext).
  • R. McShane, A. Areosa Sastre, N. Minakaran: Memantine for dementia. In: The Cochrane database of systematic reviews. Nr. 2, 2006, S. CD003154, doi:10.1002/14651858.CD003154.pub5. PMID 16625572. (Review).
  • J. Birks, Evans J. Grimley: Ginkgo biloba for cognitive impairment and dementia. In: Cochrane Database Syst Rev. Nr. 2, 2007, S. CD003120, doi:10.1002/14651858.CD003120.pub2, PMID 17443523.
  • J. Birks, E. Grimley, M. Van Dongen: Ginkgo biloba for cognitive impairment and dementia. In: Cochrane Database Syst Rev. S. CD003120, PMID 12519586.
  • S. T. DeKosky, A. Fitzpatrick, D. G. Ives, J. Saxton, J. Williamson, O. L. Lopez, G. Burke, L. Fried, L. H. Kuller, J. Robbins, R. Tracy, N. Woolard, L. Dunn, R. Kronmal, R. Nahin, C. Furberg: The Ginkgo Evaluation of Memory (GEM) study: design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. In: Contemp Clin Trials. Band 27, Nr. 3, 2006, S. 238–253, doi:10.1016/j.cct.2006.02.007, PMID 16627007.
  • B. E. Snitz et al.: Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. In: JAMA. Band 302, Nr. 24, Dezember 2009, S. 2663–2670, doi:10.1001/jama.2009.1913. PMID 20040554. PMC 2832285 (freier Volltext).
  • S. Krishnan, R. Cairns, R. Howard: Cannabinoids for the treatment of dementia. In: The Cochrane database of systematic reviews. Nr. 2, 2009, S. CD007204, doi:10.1002/14651858.CD007204.pub2, PMID 19370677 (Review).
  • S. Craft et al.: Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. In: Archives of neurology. Band 69, Nr. 1, Januar 2012, S. 29–38, doi:10.1001/archneurol.2011.233. PMID 21911655. PMC 3260944 (freier Volltext).
  • Jacobo Mintzer, Krista L. Lanctôt, Roberta W. Scherer, Paul B. Rosenberg, Nathan Herrmann: Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. In: JAMA neurology. Band 78, Nr. 11, 1. November 2021, ISSN 2168-6157, S. 1324–1332, doi:10.1001/jamaneurol.2021.3356, PMID 34570180, PMC 8477302 (freier Volltext).
  • M. W. Dysken et al.: Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. In: JAMA. Band 311, Nr. 1, Januar 2014, S. 33–44, doi:10.1001/jama.2013.282834. PMID 24381967. PMC 4109898 (freier Volltext).
  • M. Sano et al.: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. In: The New England Journal of Medicine. Band 336, Nr. 17, April 1997, S. 1216–1222, doi:10.1056/NEJM199704243361704. PMID 9110909.
  • R. C. Petersen et al.: Vitamin E and donepezil for the treatment of mild cognitive impairment. In: The New England Journal of Medicine. Band 352, Nr. 23, Juni 2005, S. 2379–2388, doi:10.1056/NEJMoa050151. PMID 15829527.
  • J. H. Kang et al.: A randomized trial of vitamin E supplementation and cognitive function in women. In: Archives of internal medicine. Band 166, Nr. 22, 2006 Dec 11-25, S. 2462–2468, doi:10.1001/archinte.166.22.2462. PMID 17159011.
  • J. H. Kang et al.: Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women’s Antioxidant and Cardiovascular Study. In: Circulation. Band 119, Nr. 21, Juni 2009, S. 2772–2780, doi:10.1161/CIRCULATIONAHA.108.816900. PMID 19451353. PMC 2752297 (freier Volltext).
  • E. R. Miller et al.: Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. In: Annals of internal medicine. Band 142, Nr. 1, Januar 2005, S. 37–46, PMID 15537682.
  • J. Cohen-Mansfield: Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. In: Am J Geriatr Psychiatry. 9 (4), 2001, S. 361–381. PMID 11739063 (Review)
  • T. E. Dunne, S. A. Neargarder, P. B. Cipolloni, A. Cronin-Golomb: Visual contrast enhances food and liquid intake in advanced Alzheimer’s disease. In: Clin Nutr. Band 23, Nr. 4, 2004, S. 533–538, PMID 15297089.
  • N. C. Berchtold, C. W. Cotman: Evolution in the conceptualization of dementia and Alzheimer’s disease: Greco-Roman period to the 1960s. In: Neurobiol. Aging. Band 19, Nr. 3, 1998, S. 173–189, PMID 9661992.
  • M. B. Graeber et al.: Rediscovery of the case described by Alois Alzheimer in 1911: historical, histological and molecular genetic analysis. In: Neurogenetics. Band 1, Nr. 1, Mai 1997, S. 73–80, PMID 10735278.
  • U. Müller, P. Winter, M. B. Graeber: A presenilin 1 mutation in the first case of Alzheimer’s disease. In: The Lancet. Neurology. Band 12, Nr. 2, Februar 2013, S. 129–130, doi:10.1016/S1474-4422(12)70307-1. PMID 23246540.

nytimes.com

rbb-online.de

redirecter.toolforge.org

  • Walter Stehling, Timo Grimmer, Alexander Kurz: Leichtes Metall mit schweren Folgen? Aluminium und die Alzheimer Krankheit. In: Archiv Alzheimer Info. DAlzG, März 2013, archiviert vom Original (nicht mehr online verfügbar) am 31. Mai 2020; abgerufen am 11. Oktober 2019.
  • APA: „Demenz fordert uns alle, Effizienz und Fürsorge sind gefragt“. Ehemals im Original (nicht mehr online verfügbar); abgerufen am 9. Juli 2021 (deutsch).@1@2Vorlage:Toter Link/science.apa.at (Seite nicht mehr abrufbar. Suche in Webarchiven)
  • Interview mit Regisseurin Barbara Wachendorff. In: Sommerblut – Festival der Multipolarkultur. 7. Mai 2012, archiviert vom Original (nicht mehr online verfügbar) am 9. August 2019; abgerufen am 9. August 2019.
  • DVD-Box Demenz. In: LVR-Klinikverbund. Landschaftsverband Rheinland (LVR), archiviert vom Original (nicht mehr online verfügbar) am 9. August 2019; abgerufen am 9. August 2019.
  • Stiller Abschied. In: daserste.de. Das Erste, archiviert vom Original am 27. September 2023; abgerufen am 27. September 2023.
  • Noch einmal, June. In: programm.ard.de. ARD, archiviert vom Original am 13. Dezember 2023; abgerufen am 13. Dezember 2023.

rochester.edu

urmc.rochester.edu

schlosstheater-moers.de

sciencedaily.com

score11.de

siemens.com

smh.com.au

spiegel.de

tagesanzeiger.ch

tagesspiegel.de

taz.de

thelancet.com

  • Hilkka Soininen et al.: 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. In: The Lancet Neurology. Band 0, Nr. 0, ISSN 1474-4422, doi:10.1016/S1474-4422(17)30332-0 (Online [abgerufen am 11. November 2017]).

tu-darmstadt.de

elib.tu-darmstadt.de

vfa.de

web.archive.org

  • Skript (Memento vom 21. September 2008 im Internet Archive) (PDF; 612 kB) der Sendung Quarks & Co zum Thema Alzheimer
  • Walter Stehling, Timo Grimmer, Alexander Kurz: Leichtes Metall mit schweren Folgen? Aluminium und die Alzheimer Krankheit. In: Archiv Alzheimer Info. DAlzG, März 2013, archiviert vom Original (nicht mehr online verfügbar) am 31. Mai 2020; abgerufen am 11. Oktober 2019.
  • National Institute on Aging: The Seven Warning Signs of Alzheimer’s Disease. (Memento vom 12. März 2009 im Internet Archive) (englisch)
  • Liz Kumru: Getting Lost in Alzheimer’s. UNMC; abgerufen am 22. Juli 2007 unmc.edu (Memento vom 10. Mai 2001 im Internet Archive)
  • Interview mit Regisseurin Barbara Wachendorff. In: Sommerblut – Festival der Multipolarkultur. 7. Mai 2012, archiviert vom Original (nicht mehr online verfügbar) am 9. August 2019; abgerufen am 9. August 2019.
  • DVD-Box Demenz. In: LVR-Klinikverbund. Landschaftsverband Rheinland (LVR), archiviert vom Original (nicht mehr online verfügbar) am 9. August 2019; abgerufen am 9. August 2019.
  • Stiller Abschied. In: daserste.de. Das Erste, archiviert vom Original am 27. September 2023; abgerufen am 27. September 2023.
  • Noch einmal, June. In: programm.ard.de. ARD, archiviert vom Original am 13. Dezember 2023; abgerufen am 13. Dezember 2023.

webmedcentral.com

welt.de

wiley.com

alz-journals.onlinelibrary.wiley.com

  • Antonios Douros, Zharmaine Ante, Carlo A. Fallone, Laurent Azoulay, Christel Renoux, Samy Suissa, Paul Brassard: Clinically apparent Helicobacter pylori infection and the risk of incident Alzheimer's disease: A population‐based nested case‐control study. In: Alzheimer's & Dementia. 13. Dezember 2023, ISSN 1552-5260, doi:10.1002/alz.13561 (wiley.com [abgerufen am 2. Januar 2024]).

youtube.com

  • Thomas Liesen (Buch und Regie), Ulrike Schweitzer (Redaktion): Leben, Lieben, Vergessen… Längengrad-Filmproduktion, 2013 Online bei YouTube.

zdb-katalog.de

  • Antonios Douros, Zharmaine Ante, Carlo A. Fallone, Laurent Azoulay, Christel Renoux, Samy Suissa, Paul Brassard: Clinically apparent Helicobacter pylori infection and the risk of incident Alzheimer's disease: A population‐based nested case‐control study. In: Alzheimer's & Dementia. 13. Dezember 2023, ISSN 1552-5260, doi:10.1002/alz.13561 (wiley.com [abgerufen am 2. Januar 2024]).
  • Jacobo Mintzer, Krista L. Lanctôt, Roberta W. Scherer, Paul B. Rosenberg, Nathan Herrmann: Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. In: JAMA neurology. Band 78, Nr. 11, 1. November 2021, ISSN 2168-6157, S. 1324–1332, doi:10.1001/jamaneurol.2021.3356, PMID 34570180, PMC 8477302 (freier Volltext).
  • Carolyn Fredericks: Methylphenidate for Apathy in Alzheimer Disease—Why Should We Care? In: JAMA Neurology. Band 78, Nr. 11, 1. November 2021, ISSN 2168-6149, S. 1311, doi:10.1001/jamaneurol.2021.2942.
  • Hilkka Soininen et al.: 24-month intervention with a specific multinutrient in people with prodromal Alzheimer’s disease (LipiDiDiet): a randomised, double-blind, controlled trial. In: The Lancet Neurology. Band 0, Nr. 0, ISSN 1474-4422, doi:10.1016/S1474-4422(17)30332-0 (Online [abgerufen am 11. November 2017]).
  • F. G. Boess, M. Lieb, E. Schneider, T. M. Zimmermann, R. Dodel: Kosten der Alzheimer-Erkrankung in Deutschland – aktuelle Ergebnisse der GERAS-Beobachtungsstudie. In: Gesundheitsökonomie & Qualitätsmanagement. Band 21, Nr. 5. Thieme, Oktober 2016, ISSN 1432-2625, S. 232–241, doi:10.1055/s-0042-100956.